Stocktoria
Annexon, Inc. ANNX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-07-24
Annexon, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $184.7M | $119.4M | $113.8M | $112.5M | $100.1M | $49.3M | $24.5M |
| Operating income | -$216.4M | -$154.1M | -$143.7M | -$145.6M | -$130.7M | -$63.5M | -$32.5M |
| Income tax | $0 | $0 | $0 | $0 | — | — | $4,000 |
| Net income | -$206.7M | -$138.2M | -$134.2M | -$141.9M | -$130.3M | -$63.4M | -$37.2M |
| EPS (diluted) | $-1.34 | $-1.01 | $-1.77 | $-2.60 | $-3.40 | — | — |
| Operating cash flow | -$186.4M | -$118.0M | -$121.1M | -$116.3M | -$106.1M | -$53.1M | -$28.4M |
| Free cash flow | -$186.5M | -$118.0M | -$121.3M | -$122.8M | -$107.8M | -$53.6M | -$28.6M |
| Cash & equivalents | $162.1M | $49.5M | $225.1M | $140.0M | $74.8M | $268.6M | $43.9M |
| Total assets | $277.6M | $350.1M | $297.7M | $285.1M | $287.0M | $355.9M | $49.9M |
| Total liabilities | $65.9M | $57.0M | $47.1M | $53.9M | $55.1M | $11.7M | $6.4M |
| Shareholders' equity | $211.6M | $293.1M | $250.6M | $231.2M | $231.9M | $344.3M | -$100.5M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.